Abstract
The ZFHX3 gene is highly expressed in the developing brain and plays vital roles in embryonic development, cell proliferation, neuronal differentiation, and neuronal death. The association between the ZFHX3 gene and human disease was undefined. This study aims to explore the relationship between ZFHX3 variants and epilepsy.
Whole-exome sequencing was performed in patients with partial epilepsy without acquired causes. Drosophila model of Zfh2 (ortholog of ZFHX3) knockdown was used to validate the association between ZFHX3 and epilepsy. The expression level of ZFHX3 in different developmental stages was analyzed by using the data in humans from the Brainspan database and in flies and mice determined by RT-qPCR.
Eight pairs of compound heterozygous variants in ZFHX3 were identified in eight unrelated cases of childhood epilepsies. All patients presented partial epilepsy, including two with early spasms and one with frequent nonconvulsive status epilepticus. The three cases with severe epilepsies also had neurodevelopmental abnormities. However, all patients became seizure-free, including the patients with spasms. These variants had no or low allele frequencies in controls and presented statistically higher frequency in the case cohort than the controls. The number of recessive ZFHX3 variants identified in this cohort was significantly more than the expected number of the East Asian population and that of the control of 1942 asymptomatic parents. Variants were predicted to be damaging by protein modeling and/or in silico prediction tools. Genotype-phenotype correlation analysis revealed that the patients with missense variants in C-terminus or C-terminus-truncated variant exhibited mild phenotype (only partial epilepsy). Knockdown of Zfh2 in flies led to increased susceptibility to seizures and abnormal firing of excitability neurons. In Drosophila, the expression of Zfh2 is high in larvae, decreased in pupae and early adults, and increased in later adults. In mice, Zfhx3 is predominantly expressed in fetuses and decreased dramatically after birth. In humans, the data from the Brainspan database showed that ZFHX3 is highly expressed in the embryonic period and decreased after birth with a nadir at approximately 10 years old. The dramatical decreasing of ZFHX3 in early life correlated with the natural course of the illness.
ZFHX3 variants were potentially associated with partial epilepsy of childhood and infant spasms. The correlation between the outcome and gene expression stage provided insight into the underlying mechanism of the natural course of illness, potentially being helpful in management of the patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the National Natural Science Foundation of China (No. 82271505 to W.-P.L. No. 81870903 to Y.-H.Y); Science and Technology Project of Guangzhou (Grant Nos 202201020106 to Liu Xiaorong, 33121030, and 33121173), Multi-center Clinical Research Fund Project of the Second Affiliated Hospital of Guangzhou Medical University (Grant Nos 010G271099, 2020-LCYJ-DZX-03 to Liao Weiping, and 2021-LCYJ-DZX-02 to Liu Xiaorong), and Scientific Research Project of Guangzhou Education Bureau (Grant No. 202235395 to Liu Xiaorong). The funders had no role in study design, data collection and analysis and decision to publish or in manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of The Second Affiliated Hospital of Guangzhou Medical University (2020-h5-49), and written informed consent was obtained from all patients or their parents.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
